Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellgram-CKD in Chronic Kidney Disease
NCT05042206Phase 1Completed
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cellgram-CKD in chronic kidney disease (CKD), sponsored by Pharmicell Co., Ltd. Primary endpoint: Incidence of Adverse Events at 12 months. Started Nov 2021; status: completed.
02
Drugs
Cellgram-CKD
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05042206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042206.